Skip to content

Can hypnosis be used to manage breathlessness and anxiety in people with severe COPD?

Hypnosis for management of breathlessness and anxiety in severe and palliative-care COPD patients: a sham-controlled crossover trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10029862
Enrollment
20
Registered
2020-01-07
Start date
2019-12-10
Completion date
Unknown
Last updated
2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea (breathlessness) in patients with severe chronic obstructive pulmonary disease (COPD) Respiratory

Interventions

Treatment: Hypnosis (15-minute script, available on request) Sham: Active listening session (15-minute script, available on request) 6-week, randomized, sham-controlle

Sponsors

Bligny Hospital Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 35-80 years 2. Affiliated to a Social Security scheme or beneficiary of such a scheme 3. Absence of neurological disease interfering with the passing of tests 4. Capable of giving free, informed consent. 5. Severe COPD with dyspnea and distension 6. Hospitalized, with or without a tracheotomy 7. Non-obese 8. Predicted FEV1 120% in pulmonary function tests 9. Severity marked by ongoing hospitalization, with at least one prior instance of decompensation 10. Dyspneic, with resting Borg Scale score =3 11. Not having yet participated in the complementary care protocol offered by the hospital, a pulmonary rehabilitation program (PRP) protocol, or any hypnosis protocol

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Mechanical ventilation during the session 3. Known severe cardiac insufficiency 4. Known severe pulmonary arterial hypertension 5. Cancer diagnosis 6. Significant cognitive impairment, hypercapnic encephalopathy or confusional syndrome 7. Deafness 8. Anemia (hemoglobin =8 g/dl) 9. Psychotic pathology 10. Anti-epileptic treatment

Design outcomes

Primary

MeasureTime frame
Anxiety assessed using the STAI-6 questionnaire at baseline and immediately after intervention

Secondary

MeasureTime frame
1. Respiratory rate in cycles/min measured manually, following the accepted standard procedure, at baseline and immediately after intervention 2. Oxygen saturation (SpO2) measured with a pulse oximeter at baseline and immediately after intervention

Countries

France

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 17, 2026